Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences
Transaction continues a frenzy of M&A activity this year in the healthcare sector
Related reading
Thermo Fisher aims to sell parts of its diagnostics business for $4bn
Deal would mark latest move by a life sciences group to jettison lower-growth assets
Amgen swoops on UK cancer biotech in deal worth up to $840mn
Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022
TPG and Blackstone near deal for medical technology company Hologic
Acquisition by private equity groups would be one of the biggest take-private deals of the year
23andMe founder buys back genetic testing company in second auction
Anne Wojcicki pays $305mn to defeat a previous deal struck with Regeneron Pharmaceuticals
US to speed up payments for new medical devices
Regulators hand industry a lobbying victory after fierce effort to get faster coverage for their products
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year